LPCN Lipocine Inc

Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.

$1.07  +0.06 (5.94%)
As of 12/06/2021 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/15/2012
Outstanding shares:  88,290,650
Average volume:  579,816
Market cap:   $89,173,557
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    53630X104
ISIN:        US53630X1046
Sedol:      
Valuation   (See tab for details)
PE ratio:   -9.55
PB ratio:   2.88
PS ratio:   0.00
Return on equity:   -54.16%
Net income %:   -32,298.98%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy